HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Symrise posts 2008 results

This article was originally published in The Rose Sheet

Executive Summary

U.S. acquisitions help boost sales for the fragrance and flavors firm by 25% to roughly $1.65 bil. in fiscal 2008, Symrise announces March 4. Firm bought Intercontinental Fragrances and Manheimer Fragrances in October (1"The Rose Sheet" Oct. 6, 2008, p. 10). Net of acquisitions, sales increased by 3.5% in local currencies. Symrise says it made "additional progress" by tapping the sales potential of large multinational customers and fast-growing emerging markets. Sales in emerging markets grew by 8% and claimed 39% of total sales in 2008, firm notes. Sales for firm's Scent & Care division were roughly even with 2007, at approximately $842.4 mil. for the year. Economic crisis is likely to produce a weaker first half of 2009 as compared with the prior-year period, but Symrise expects to grow faster than the market. "Despite the challenging business environment, we consider our core business to be as stable and robust as ever," CEO Gerold Linzbach says

You may also be interested in...

Symrise Continues To Grow Business, Buying Two Air-Care Scent Developers

Symrise acquires Intercontinental Fragrances and Manheimer Fragrances - increasing its stake in the $300 million North American air-care market - in its latest play for a bigger slice of the global flavors and fragrances pie

UCB Pins Growth Hopes On Burgeoning Late-Stage Pipeline

UCB's R&D efforts include late-stage diverse but complementary immunologicals and anti-neuroinflammatories.


New Indications For Diabetes Drugs Under The Spotlight At EMA

Janssen and AstraZeneca are among a raft of companies that might this week find out whether the European Medicines Agency will recommend approval of their products for expanded therapeutic indications.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts